Edwards gains CE mark for first transcatheter tricuspid treatment

Daniel Allar | | Cardiovascular Business | Structural Heart Disease
Edwards Lifesciences logo

Subscribe to Cardiovascular Business News

""
Daniel Allar

Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.

Related Content

EARLY TAVR update: New data highlight continued benefits of treating asymptomatic aortic stenosis
TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data
AI company founded by cardiologist gains FDA clearance, raises $8.5M
Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis
High-intensity ultrasound technology for calcified valve leaflets makes debut in Europe
Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes

Around the web

Health Exec
Is the No Surprises Act working? Government watchdog is uncertain
Health Exec
Health system CEO fired without cause in wake of class-action lawsuit over unnecessary surgeries
Radiology Business
AI-powered brain tumor segmentation tool earns clearance in US

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News